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Smith-Lemli-Opitz syndrome (SLOS) is an 
autosomal recessive genetic disease with an 
incidence of 1 in 50,000. It is characterized 
by mental retardation, microcephaly, syndac-
tyly of the toes, and other dysmorphic features 
and problems related to abnormal growth and 
development. SLOS is caused by mutation 
of the 3β-hydroxysterol-∆7-reductase gene 
(DHCR7), which converts 7-dehydrocholes-
terol (DHC) to cholesterol (1–3). SLOS-af-
fected individuals have increased plasma levels 
of DHC and abnormally low levels of choles-
terol. Many of these patients experience for-
mula and food intolerance. Because mast cells 
are central in allergy and cholesterol-enriched 
liquid-ordered domains (lipid rafts) play an im-
portant role in their activation (4, 5), it was of 
interest to study whether the loss of cholesterol 
altered mast cell sensitivity and activation. Mice 
carrying a null mutation of the 3 β-hydroxys-
terol-∆7-reductase gene (Dhcr7−/−, referred to 
as DHCR KO throughout) were developed 
as a model for SLOS (6). These mice failed to 
produce cholesterol and accumulated DHC 
in serum and tissue. Due to a failure to nurse, 
newborn mice die shortly after birth. We were 
able, however, to cultivate mast cells from the 
liver progenitors of DHCR KO mice.
Cholesterol plays an important role in 
membrane organization (7, 8). The plasma 
membrane has specialized regions that are char-
acterized by high concentrations of cholesterol 
and sphingolipids and spontaneously segregate 
and are insoluble in nonionic detergents (9). 
Antigen (Ag)-induced aggregation of FcεRI-
bound IgE antibodies causes inclusion of this 
receptor in these specialized regions commonly 
referred to as lipid rafts. Lyn kinase is also con-
centrated in lipid rafts (4, 5) and weakly associ-
ates and phosphorylates FcεRI (10). Whether 
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the recruitment of FcεRI into lipid rafts is necessary for its 
interaction with Lyn and for initiation of its phosphorylation, 
or whether lipid rafts serve to sustain and/or amplify the 
  receptors’ phosphorylation remains unresolved. The mouse 
SLOS model studied herein provided a system where deple-
tion of cholesterol could be achieved as a consequence of 
gene deletion. Because cholesterol plays a crucial role in 
membrane domains with signal transduction potential (8), 
  investigating the molecular consequences of cholesterol defi  -
ciency and DHC accumulation in mast cell function could 
yield new insights for understanding the pathophysiology un-
derlying SLOS and disease treatment.
RESULTS
Mast cells defi  cient in 3-𝗃-hydroxysterol-𝖫7-reductase 
accumulate DHC
Mast cell progenitors from both DHCR KO and WT mice 
were cultivated in medium with cholesterol. DHCR KO 
mast cells cultivated in medium containing 10% FBS pro-
liferated and diff  erentiated similarly to WT mast cells. No 
substantial diff  erences were found in global tyrosine phos-
phorylation of proteins, intracellular calcium release, or in 
degranulation of DHCR KO mast cells cultivated under these 
conditions (Fig. 1 A and not depicted). Cholesterol levels 
were the same in DHCR KO and WT mast cells (Table I, 0 h), 
demonstrating that growth of these cells in medium contain-
ing cholesterol bypassed the defect of 3-β-hydroxysterol-∆7-
reductase mutation.
To reveal the biosynthetic defect, mature DHCR KO 
or WT mast cells were cultured in medium supplemented 
with lipoprotein-defi  cient serum (LPDS). Cell viability, as 
determined by propidium iodide staining, and sterol con-
tent were measured up to 120 h after depletion. WT mast 
cells proliferated in medium without cholesterol for 120 h 
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20051701/DC1) without a signifi  cant decrease in cell 
viability (Table I). Cholesterol content decreased within 48 
to 72 h of depletion by  30% and subsequently increased to 
reach original levels by 120 h, demonstrating activation of 
cholesterol biosynthesis. Desmosterol, a precursor of choles-
terol, was also detected in WT mast cells at 48 and 72 h but 
not at 0 h (Table I). Levels of desmosterol reached  20–30% 
of t  otal sterol at 72 h. In contrast, DHCR KO cells pref-
erentially accumulated DHC as the cholesterol content de-
creased (  Table I), and DHC levels peaked at  30% of total 
sterols between 72 and 96 h of depletion. Total sterol content 
was relatively constant in WT cells but decreased slightly in 
DHCR KO cells. DHCR KO mast cells also proliferated 
poorly (Fig. S1) and cell viability decreased with time (Table I). 
When grown for 168 h in LPDS, cell viability was <70% 
(not depicted).
Subsequent experiments were performed with cells 
grown in LPDS for 72 h, as cell viability was normal and 
the ratio of DHC or desmosterol to total sterol was maxi-
mal (Table I). The numbers of apoptotic cells did not diff  er 
substantially between cholesterol-depleted and nondepleted 
cells and did not exceed 7% of total cells (Fig. 1 B). FcεRI 
expression before or after cholesterol depletion was similar 
among WT and DHCR KO mast cells (Fig. 1 C). Thus, 
for further experiments, we compared cholesterol-depleted 
DHCR KO mast cells with cholesterol-depleted or non-
depleted WT mast cells.
Loss of cholesterol and accumulation of DHC in mast cells 
result in Fc𝗆RI-dependent hyperresponsiveness
FcεRI-dependent degranulation of cholesterol-depleted DHCR 
KO cells showed a 2.8-fold increase (P < 0.006, n = 15) 
over nondepleted WT mast cells in release of the granule 
marker hexosaminidase (Fig. 2, A and B). Cholesterol-
  depleted WT cells also showed a twofold increase (P < 0.02, 
Figure 1.  Characterization of mast cell Fc𝗆RI expression, survival, 
and function from DHCR KO mice. (A) Mast cells derived from the liver 
progenitors of WT or DHCR KO mice were cultivated in medium with nor-
mal FBS, IL-3, and stem cell factor for 4 wk. Cells were sensitized with 
DNP-specifi  c IgE for 60 min and activated by exposure to the indicated 
con  centration of DNP-HSA for 20 min. Hexosaminidase release is expressed 
as a percentage of total cellular hexosaminidase. Data is mean ± SEM 
from four individual experiments. (B) Apoptotic cells were stained with 
PE-labeled annexin V in WT nondepleted or WT and DHCR KO cells de-
pleted in cholesterol-free medium for 72 h and analyzed by FACS. One 
representative of >12 individual cultures is shown. (C) WT or DHCR KO 
mast cells were cultivated in normal or cholesterol-free medium for 72 h 
and loaded with IgE, washed, and followed by FITC-labeled anti-IgE anti-
body. Level of FcεRI expression was determined as the mean fl  uorescence 
intensity (MFI) in FITC anti-IgE–stained cells compared with isotype con-
trol. Data is mean ± SD from three individual experiments.JEM VOL. 203, May 15, 2006  1163
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n = 15) relative to nondepleted WT cells. Total amounts of 
cellular hexosaminidase did not diff  er.
This suggested that the augmentation of degranulation 
resulted from cholesterol depletion and/or accumulation of 
DHC. To test this, cholesterol-depleted WT and DHCR 
KO mast cells were reconstituted with cholesterol by cultiva-
tion in medium containing 30% FBS for 30 min. The con-
centration of cholesterol in the repleted WT and DHCR KO 
cells increased to levels equivalent to nondepleted cells as 
  determined by gas chromatography (GC)/mass spectrometry
(Table I and not depicted). Cholesterol repletion of WT mast 
cells reduced degranulation to the level of nondepleted WT 
mast cells (Fig. 2 C). In contrast, cholesterol-repleted DHCR 
KO mast cells still had enhanced degranulation relative to 
cholesterol-repleted or nondepleted WT mast cells. This sug-
gested that the accumulation of DHC in DHCR KO mast 
cells, but not the accumulation of desmosterol in WT cells, 
contributed to the maintenance of enhanced degranulation. 
The concentration of DHC (R2 = 0.6094, P < 0.03), but 
not the concentration of cholesterol (R2 = 0.0246, P > 0.70) 
or of total sterol (R2 = 0.0114, P > 0.80; not depicted), cor-
related with increased degranulation (Fig. 2, D and E) in 
DHCR KO mast cells. In contrast, cholesterol correlated 
(R2 = 0.740, P < 0.01) with degranulation of cholesterol-
depleted WT (Fig. 2 F). Thus, control of WT mast cell de-
granulation appeared to be dependent on cholesterol, whereas 
DHC caused an irreversible enhancement of degranulation. 
The observed eff  ect of cholesterol or DHC on mast cell de-
granulation was upstream of the exocytotic machinery be-
cause PMA and calcium ionophore A23187 (a stimulus that 
bypasses early signaling events) led to similar degranulation 
from cholesterol-depleted or nondepleted cells (Fig. 2 G). 
Granule membrane integrity (as determined with toluidine 
blue) did not diff  er as a consequence of cholesterol depletion 
or gene alteration (not depicted).
As shown in Fig. 2 H, constitutive secretion of both IL-6 
and TNF was observed after cholesterol depletion. Consti-
tutive TNF secretion by DHCR KO mast cells was consi-
derable (105 ± 6.3 pg/ml/106 cells), reaching  40% of 
the response of stimulated WT control cells (246 ± 17.1 
pg/ml/106 cells). FcεRI stimulation did not substantially 
augment this secretion. IL-6 secretion was also constitutive 
after cholesterol depletion of DHCR KO (223 ± 9 pg/ml/
106 cells), reaching approximately one third the level of 
  stimulated control WT mast cells (643 ± 37 pg/ml/106 cells). 
For   cholesterol-depleted WT mast cells, IL-6 secretion was 
also constitutive and signifi  cant (P < 0.05, n = 4) relative to 
nondepleted cells. For TNF, a consistent but not signifi  cant 
(P < 0.09) increase was observed. Thus, the higher consti-
tutive secretion of IL-6 and TNF from cholesterol-depleted 
DHCR KO cells suggested that the accumulation of DHC 
played an important role in the enhanced cytokine response.
Accumulation of DHC in lipid rafts partially decreases 
their stability
To gain an understanding of the role of DHC in cell mem-
branes, we isolated lipid rafts from WT and DHCR KO mast 
cells. Both cholesterol and DHC were considerably parti-
tioned to these domains (Fig. 3 A). The lipid raft fractions 
(1–4) contained 60 ± 2% of the total cholesterol, and the rel-
ative distribution of cholesterol did not change during deple-
tion (Fig. 3 A), although the absolute amount of cholesterol 
decreased in WT cells at 72 h (Table I). For DHCR KO mast 
cells, the DHC content in lipid rafts was 84 ± 14% of the to-
tal DHC in these cells, and the amount of total sterols in lipid 
rafts was slightly increased. We subsequently tested whether 
the presence of DHC in lipid rafts infl  uenced their stability. 
The ease of solubility in Triton X-100 was used as a measure 
of lipid raft stability (11). Multilamellar lipid vesicles were 
prepared from cellular lipids, and solubility was measured in 
0.075 and 0.1% Triton X-100. As shown in Fig. 3 B, multi-
lamellar vesicles from cholesterol-depleted DHCR KO mast 
cells had signifi  cantly higher solubility compared with vesi-
cles from cholesterol-depleted or nondepleted WT cells. The 
relative eff  ectiveness of methyl-β-cyclodextrin (MBCD) to 
remove cholesterol from the plasma membrane is also indica-
tive of cholesterol packing and lipid raft stability (12). Incu-
bation of cells with 5mM MBCD demonstrated more effi   cient 
extraction of cholesterol from DHCR KO mast cells than 
from depleted or nondepleted WT cells (Fig. 3 C). These 
diff  erences were signifi  cant and consistent with the in vitro 
experiments shown in Fig. 3 B.
Table I.  Effect of cholesterol depletion on mast cell sterol content and viability
Time of cholesterol 
depletion (h) 
DHCR KO WT
Cholesterol 
(μg/mg of protein)
DHC 
(μg/mg of protein)
Viability 
(%)
Cholesterol 
(μg/mg of protein)
Desmosterol 
(μg/mg of protein)
Viability 
(%)
0   3.6 ± 0.3 (10)   0.3 ± 0.1 (10) 96.4 ± 0.3 (6)   3.9 ± 0.3 (10) nd 96.9 ± 0.3 (6)
48 2.6 ± 0.2 (3) 0.5 ± 0.1 (3) 95.1 ± 0.1 (3) 2.7 ± 0.2 (3) 0.6 ± 0.3 (3) 96.8 ± 0.2 (3)
72   2.2 ± 0.3 (10)   0.9 ± 0.4 (10) 93.6 ± 0.3 (6)   2.9 ± 0.3 (10) 1.3 ± 0.5 (3) 96.9 ± 0.1 (6)
96 1.9 ± 0.1 (3) 1.1 ± 0.2 (3) 89.7 ± 0.6 (3) 3.3 ± 0.1 (3) nd 95.2 ± 0.3 (3)
120 2.4 ± 0.2 (4) 1.1 ± 0.1 (4) 89.3 ± 0.8 (3) 3.4 ± 0.1 (5) nd 95.0 ± 0.2 (3)
Cells were depleted of cholesterol by incubation for the indicated times in medium containing LPDS. Cell viability was monitored by trypan blue exclusion and propidium 
iodide staining. Content of cholesterol, DHC, and desmosterol was determined by GC/mass spectrometry analysis of extracted sterols. DHC was also measured in cholesterol-
depleted WT cells but was nondetectable (sensitivity of assay is pg/mg of protein, n = 5). Total sterols did not differ signifi  cantly among genotypes before or after cholesterol 
depletion (0 vs. 72 h). Data shown are the mean ± SEM for replicate numbers as indicated in parenthesis. nd, not detected.1164  MAST CELL RESPONSES IN AN SLOS MOUSE MODEL | Kovarova et al.
Cholesterol depletion by MBCD can alter the localiza-
tion of proteins associated with lipid rafts (13). We proposed 
that the cholesterol to DHC shift in cholesterol-depleted 
DHCR KO mast cells might cause or enhance alterations in 
protein localization. A substantial decrease in the previously 
described (4) lipid raft localization of FcεRI was observed in 
cholesterol-depleted DHCR KO mast cells (29.6 ± 4.1%) 
when compared with cholesterol-depleted (40.7 ± 2.4%) or 
nondepleted (43.4 ± 4.1%) WT mast cells (Fig. 4 A). These 
changes were not due to decreased FcεRI expression (Fig. 
1 C) or to decreased recovery of soluble FcεRI as determined 
by bound radiolabeled IgE (WT/WT-/DHCR KO- = 
1.0:1.02 ± 0.07:0.987 ± 0.09). A large fraction of Lyn kinase 
is also associated with lipid rafts in mast cells (14). This asso-
ciation may well depend on lipid raft stability given that the 
Figure 2.  Cholesterol depletion and accumulation of DHC up-
  regulates mast cell degranulation and cytokine production. (A) WT and 
DHCR KO cells were cholesterol depleted (DHCR KO, WT-) or not (WT) for 
72 h. The cells were sensitized with DNP-specifi  c IgE for 60 min and acti-
vated by exposure to the indicated concentration of DNP-HSA for 20 min. 
Hexosaminidase release is expressed as a percentage of total cellular 
  hexosaminidase. (B) Quantitative analysis of hexosaminidase release 
  expressed as fold increase in cholesterol-depleted and nondepleted cells. 
The mean of hexosaminidase release calculated as in A from 15 experi-
ments is shown above each genotype. *, P < 0.02; **, P < 0.006. (C) WT 
and DHCR KO cells were depleted as in A, sensitized with IgE, and culti-
vated for 30 min in media containing high levels of cholesterol. Hexosa-
minidase release (evaluated as in A) was compared with nondepleted WT 
mast cells. (D) Correlation of DHC with hexosaminidase release (*, P < 0.02) 
in DHCR KO cells. (E) Correlation of cholesterol with hexosaminidase 
  release (*, P > 0.70) in DHCR KO cells. (F) Correlation of cholesterol with 
hexosaminidase release (*, P < 0.01) in WT cells. (G) Hexosaminidase re-
lease of cholesterol-depleted WT and DHCR KO mast cells and nonde-
pleted WT mast cells treated with 20 ng/ml PMA and the indicated 
concentration of the calcium ionophore A23187. (H) IL-6 and TNF secre-
tion in nondepleted (WT) and cholesterol-depleted (WT- and DHCR KO-) 
mast cells. Secreted cytokines were measured after cholesterol depletion 
from nonstimulated (−) or 10 ng/ml Ag-stimulated (+) cells. Data is the 
mean ± SEM from four individual experiments. *, P < 0.05; **, P < 0.01; 
***, P < 0.001.
Figure 3.  DHC reduces the stability of lipid rafts in mast cells. 
(A) Sterol analysis of sucrose density gradient fractions was performed by 
GC followed by mass spectrometry. Fractions 1–4 represent detergent-resistant 
membranes (lipid rafts). Amount of sterols is expressed as a percentage of 
the sterol found in the indicated pooled fractions compared with the total 
found in all fractions. (B) Solubility of multilamellar lipid vesicles prepared 
from cellular lipids was measured as a decrease of absorbance at 380 nm 
in 0.075 and 0.1% Triton X-100 at 30°C. Solubility is expressed as a per-
centage of the solubilized liposomes. *, P < 0.01 and < 0.03 for 0.075 
and 0.1% Triton, respectively. (C) Cells were treated with 5 mM MBCD for 
the indicated time. The extracted cholesterol is reported as a percentage 
of the amount of cholesterol in MBCD-treated cells compared with the 
amount of cholesterol in nontreated cells. *, P < 0.02; **, P < 0.003. Data 
shown are from a minimum of three individual experiments.JEM VOL. 203, May 15, 2006  1165
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detectable fraction of Lyn within these domains can vary de-
pending on the solubilization conditions (15). Solubilization 
of WT cells in 0.1% Triton X-100 showed that 51 ± 5% of 
total cellular Lyn was associated with lipid rafts (Fig. 4, B and 
C; n = 6). Depletion of cholesterol from WT cells decreased 
the amount of Lyn associated with lipid rafts to 36 ± 6%. 
Localization of Lyn to lipid rafts, however, was dramatically 
reduced (20 ± 8%, P < 0.009) when cholesterol was de-
pleted from DHCR KO mast cells. Total recovery of cellular 
Lyn, as determined by densitometry of immunoblots, did not 
diff   er substantially (Fig. 5 A, WT/WT-/DHCR KO- = 
1.0:0.923 ± 0.09:0.992 ± 0.14). Fyn kinase ( 20 ± 5% of 
total) and the adaptor LAT ( 80 ± 4% of total) also associate 
with lipid rafts in mast cells. However, neither cholesterol 
depletion nor DHC accumulation caused a substantial change 
in Fyn or LAT association with lipid rafts (Fig. 4, B and C). 
Quantitation of Fyn content in lipid rafts of cholesterol-
  depleted DHCR KO mast cells showed considerable varia-
bility; however, no considerable diff  erence was found among 
the genotypes (percentage; WT, 22 ± 2.4; WT-, 22 ± 1.9; 
DHCR KO-, 21 ± 7.7; n = 6). Recovery of total cellular 
Fyn was similar among the genotypes (WT/WT-/DHCR 
KO- = 1.0:0.936 ± 0.11:0.947 ± 0.17). Collectively, the 
fi  ndings demonstrate that decreased lipid raft stability causes 
selective loss of some proteins (like Lyn kinase) from these 
domains, which might alter cellular signaling and responses.
Cholesterol depletion and DHC accumulation alter Fc𝗆RI-
mediated early signaling upstream of calcium responses
The selective delocalization of Lyn kinase from lipid rafts in 
cholesterol-depleted DHCR KO mast cells led us to explore 
its cellular activity. To formally address the issue of the eff  ect 
of Lyn displacement on its activity, we isolated Lyn from 
whole cell lysates as well as from the lipid raft fractions of 
nondepleted or cholesterol-depleted WT and DHCR KO 
mast cells. Fig. 5 A shows that the total Lyn kinase activity in 
cholesterol-depleted WT and DHCR KO mast cells did not 
diff  er substantially from that in nondepleted WT mast cells. 
In contrast, Lyn activity in lipid rafts was dramatically de-
creased upon cholesterol depletion of WT and DHCR KO 
mast cells relative to nondepleted WT mast cells (Fig. 5 B). 
The loss of Lyn activity in these domains led us to assess the 
phosphorylation of FcεRI in cholesterol-depleted DHCR 
KO cells. Fig. 5 C shows that the overall phosphorylation of 
FcεRI was decreased by cholesterol depletion. Densitometric 
quantitation demonstrated signifi  cant diff  erences (*, P < 0.05; 
**, P < 0.01; n = 4). Although the kinetics were unaltered, 
the extent of FcεRIβ and FcεRIγ phosphorylation was 
  reduced by  30–40%.
Downstream of Lyn kinase, Syk kinase is activated by 
binding the ITAM sequences in the cytoplasmic domain 
of the γ subunit of FcεRI. Tyrosine (Y)346 in the linker 
region of Syk has been reported to be involved in the in-
teraction and/or tyrosine phosphorylation and activation of 
phospholipase C-γ (PLCγ; reference 16). The linker region 
tyrosines are also possible targets of Lyn kinase activity (17). 
Phosphorylation of Syk Y346 in nondepleted WT mast cells 
was rapid (1 min) and increased sixfold after Ag stimulation 
(Fig. 5 D). In contrast, Syk Y346 phosphorylation in choles-
terol-depleted WT and DHCR KO cells was delayed (>3 
min) and reduced in magnitude ( 50% inhibition). LAT, 
the adaptor that scaff  olds a signaling complex that includes 
PLCγ, is a target of Syk activity (18). Because we previ-
ously showed that Y195 of LAT contributes to stable PLCγ 
binding (19), we used a phosphospecifi  c antibody to assess 
its phosphorylation. As shown in Fig. 5 D, phosphorylation 
of LAT in nondepleted WT mast cells increased by eight-
fold after FcεRI stimulation with maximal phosphorylation 
at 3 min. Depletion of cholesterol signifi  cantly prolonged 
Figure 4.  Reduced stability of lipid rafts in mast cells delocalizes 
select proteins. (A) Mast cells were labeled with [125I]-IgE and activated 
with 100 ng/ml Ag for 6 min, and then solubilized in 0.1% Triton X-100. 
The percentage of FcεRI associated with detergent-resistant fractions 
(lipid rafts) was calculated from the lipid raft–associated cpm and the 
cpm in the entire gradient. **, P < 0.001 relative to WT. (B) Fractions of 
sucrose gradient that were analyzed are indicated along with increasing 
sucrose concentrations. Lyn, Fyn, and LAT were identifi  ed with specifi  c 
antibodies. One representative of six experiments is shown. (C) Statistical 
analysis of Lyn, Fyn, and LAT association with lipid rafts (**, P < 0.009) for 
all experiments.1166  MAST CELL RESPONSES IN AN SLOS MOUSE MODEL | Kovarova et al.
LAT Y195 phosphorylation for both WT and DHCR KO 
mast cells with peak responses reaching sixfold that of non-
stimulated/nondepleted WT cells. Interestingly, DHCR 
KO mast cells showed a delay in maximal Y195 phosphory-
lation, demonstrating that the accumulation of DHC altered 
the kinetics. The sustained LAT phosphorylation suggested 
that PLCγ phosphorylation was unaltered, and no substantial 
diff  erences were observed in the phosphorylation of PLCγ1 
or PLCγ2 (not depicted). This was consistent with the small 
diff  erences in the calcium response of nondepleted and cho-
lesterol-depleted cells when normalized to the actual calcium 
concentration of each cell type after Fura 2 loading (Fig. 
5 E). Thus, the fi  ndings demonstrate that the delocalization 
of a considerable fraction of Lyn protein after cholesterol 
depletion of DHCR KO mast cells reduced FcεRI phos-
phorylation, delayed Syk activation, and delayed LAT phos-
phorylation. However, the extent of LAT phosphorylation 
did not diff  er substantially from that of WT cells, consistent 
with no detectable alteration in PLCγ phosphorylation and 
calcium responses.
Cholesterol depletion enhances Fyn-mediated signaling; 
similarities with Lyn defi  ciency in mast cells
We and others previously demonstrated that the absence of 
Lyn in mast cells resulted in increased Fyn kinase activity and 
degranulation (20, 21). Failure to phosphorylate the Csk-bind-
ing protein (Cbp/PAG) and recruit the negative regulatory 
kinase, COOH-terminal Src kinase (Csk), was demonstrated 
as contributory to increased Fyn kinase activity (20). Because 
Cbp is present in lipid rafts, we speculated that Cbp phos-
phorylation might be impaired in cholesterol-depleted WT 
and DHCR KO mast cells. Phosphotyrosine analysis of im-
munoprecipitated Cbp demonstrated that cholesterol deple-
tion of WT and DHCR KO mast cells resulted in decreased 
phosphorylation (Fig. 6 A). For cholesterol-depleted DHCR 
KO mast cells, the extent of phosphorylation was more ap-
preciably reduced (greater than twofold diff  erence relative 
to cholesterol-depleted WT cells). The activity of Fyn was 
increased three- to fi  vefold in cholesterol-depleted WT and 
DHCR KO mast cells relative to the nondepleted WT mast 
cells (Fig. 6 B).
Figure 5.  Reduced Lyn kinase activity and altered Syk, LAT, and 
Fc𝗆RI phosphorylation, but not calcium mobilization, in cholesterol-
depleted WT and DHCR KO mast cells. In vitro kinase activity of 
immuno  precipitated Lyn (autophosphorylation) isolated from total cell 
lysates (A) or from the lipid raft fractions (B). For total and lipid raft–
localized Lyn, activity is normalized to that activity in nondepleted WT 
cells. One representative of four individual experiments is shown. (C) Cho-
lesterol-depleted WT and DHCR KO and nondepleted WT mast cells were 
activated with 100 ng Ag for the indicated time. IgE–FcεRI complexes 
were immunoprecipitated from the postnuclear supernatant using anti-
bodies specifi  c to IgE. Blots were probed with anti-phosphotyrosine–
specifi  c antibody 4G10 and anti-γ antibody. Fold increase is shown as a 
graph and was determined from three individual experiments. (D) Phos-
phorylation of Syk (Y346) and LAT (Y195) in cholesterol-depleted WT and 
DHCR KO mast cells as well as in nondepleted WT cells as detected with 
phosphospecifi  c antibody. Fold induction refl  ects the increase in phospho-
protein/protein normalized to nonstimulated WT cells (1.0) in all 
panels. LAT (Y195) phosphorylation in cholesterol-depleted WT and DHCR 
KO mast cells as well as in nondepleted WT cells was detected with phos-
phospecifi  c antibody. (E) Cholesterol-depleted WT and DHCR KO mast cells 
as well as nondepleted WT cells were loaded with Fura 2, and calcium 
mobilization was measured by fl  uorescence spectroscopy. Calcium mobili-
zation is shown as the intracellular calcium concentration over time. 
  Arrow indicates the addition of 20 ng Ag.JEM VOL. 203, May 15, 2006  1167
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Our previous studies established that Fyn kinase is able to 
regulate the phosphorylation of Gab2 (22), an adaptor mole-
cule demonstrated by others to directly modulate the activity 
of phosphatidylinositol 3-OH kinase (PI3K) and found to 
be essential for mast cell degranulation (23). To determine 
whether enhanced PI3K activity played a role in the en-
hanced degranulation phenotype observed upon cholesterol 
depletion, we treated cholesterol-depleted DHCR KO and 
WT cells with the PI3K-specifi   c inhibitor, LY 294002. 
Cholesterol depletion of DHCR KO and WT mast cells 
caused increased resistance to this inhibitor (Fig. 6 C). At the 
suboptimal concentration of 10 μM, the degranulation of 
nondepleted WT mast cells was inhibited by 15.2 ± 2.1%, 
whereas degranulation of cholesterol-depleted WT and 
DHCR KO mast cells was inhibited by 5.1 ± 2.1% and 5.9 ± 
1.8% (P < 0.001, n = 3), respectively. To further verify 
  increased PI3K activity, we measured the phosphorylation 
of Akt, a kinase whose activity is dependent on PI3K-
  generated PIP3. Phosphorylation of S473 of Akt in FcεRI-
stimulated cholesterol-depleted DHCR KO cells was 
increased almost threefold compared with nondepleted WT 
and twofold relative to cholesterol-depleted WT mast cells 
(Fig. 6 D). Importantly, cholesterol depletion led to a two-
fold increase in constitutive phosphorylation of Akt in 
DHCR KO mast cells. This increase in Akt phosphorylation 
was consistent with our prior fi  ndings of increased constitu-
tive S473 phosphorylation in Lyn-null bone marrow– derived 
mast cells (22).
DISCUSSION
Herein, we describe a genetic model in which mutation of 
the 3β-hydroxysterol ∆7-reductase gene caused reduction of 
cholesterol in the absence of an exogenous agent. This SLOS 
model provides the fi  rst in vivo evidence in a genetic model 
that DHC can partition to lipid raft domains and cause lipid 
raft dysfunction. Previous fi  ndings, using artifi  cial membranes 
or pharmacological inhibitors of 3β-hydroxysterol ∆7-reduc-
tase, demonstrated that DHC is able to incorporate into lipid 
rafts and partitions more eff  ectively than cholesterol (24). We 
now fi  nd that DHC is able to maintain the structural integrity 
of lipid rafts, albeit with clear diff  erences in domain stability 
and cell signaling. In contrast, desmosterol (the sterol accu-
mulating in cholesterol-depleted WT cells) partitions poorly 
to lipid rafts but has been demonstrated to partly alter cell 
signaling (25). However, accumulation of desmosterol in 
cells was more variable and together with the reduced levels 
of cholesterol in WT cells (at 72 h of depletion) could pro-
vide an explanation for the milder and more variable pheno-
type (degranulation, cytokine production, lipid raft instability, 
and Lyn displacement) of the cholesterol-depleted WT mast 
cells. Regardless, the reversal of the hyper-degranulation in 
cholesterol-depleted WT cells by repletion of cholesterol 
demonstrated that this sterol principally accounts for the al-
teration of degranulation observed for WT cells. This is con-
sistent with the prior fi  nding that acute lowering of cholesterol 
enhances mast cell degranulation (26). The implication is that 
altered localization of signaling proteins, as a consequence of 
Figure 6.  Up-regulation of Fyn kinase activity as a consequence 
of cholesterol depletion and DHC accumulation. (A) Cbp from choles-
terol-depleted WT and DHCR KO mast cells as well as from nondepleted 
WT mast cells was immunoprecipitated with goat antibody to Cbp and 
probed with anti-phospho tyrosine and rabbit antibody to Cbp. Fold in-
duction refl  ects the increase in phospho-protein/protein normalized to 
nonstimulated WT cells (1.0) in all panels. (B) In vitro kinase activity of Fyn 
before and after activation. Fyn kinase was immunoprecipitated from cell 
lysates and incubated in the presence of [32P]-labeled ATP and dephos-
phorylated casein as a substrate for 20 min at 30°C. Both autophosphory-
lation and substrate phosphorylation are shown. (C) Mast cells were 
treated or not with the indicated concentrations of LY294002 and acti-
vated with 10 ng DNP-HSA, and hexosaminidase release was measured in 
three individual experiments. Release (%) is normalized to Ag-stimulated 
cells (100%) in the absence of LY294002. ***, P < 0.001; **, P < 0.01. 
Spontaneous release ( 4%) did not differ in the presence or absence of 
the inhibitor. (D) Activation of Akt in cholesterol-depleted WT and DHCR 
KO mast cells as well as nondepleted WT mast cells. Phosphorylation was 
analyzed by probing of cell lysates after activation with 100 ng Ag using 
phosphospecifi  c antibody to S473 of Akt. Fold increase in phosphorylation 
for all experiments is from a minimum of three individual experiments 
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either cholesterol defi   ciency and/or DHC accumulation, 
contributes to the SLOS phenotype.
Several studies promote the view that cholesterol is key in 
compartmentalizing signaling during growth, diff  erentiation, 
and function. In the immune system, tolerance-sensitive 
transitional immature B cells with low levels of cholesterol 
showed impaired localization of the B cell Ag receptor in 
lipid rafts after engagement of this receptor, as well as altered 
signaling (27). In embryonic development, Hedgehog signal-
ing requires cholesterol for its appropriate function. Sonic, 
Indian, and Desert Hedgehogs, which are involved in limb 
and midline pattern formation, bone mineralization, and 
genital development, respectively, are covalently modifi  ed by 
the addition of cholesterol to their amino-terminal signaling 
domain, which is required for their appropriate function 
(28, 29). The work of Drs. Baird and Holowka has provided 
  ample evidence of a key role for cholesterol-enriched lipid 
rafts in FcεRI phosphorylation and mast cell activation. The 
evidence is multifaceted: (a) the fraction of FcεRI found in 
cholesterol-rich membranes is rapidly increased upon receptor 
engagement, and these regions also contain a large fraction of 
Lyn kinase (4, 14); (b) the active fraction of Lyn kinase is pri-
marily found in cholesterol-rich membranes, and this envi-
ronment protects included proteins from dephosphorylation 
by phosphatases (30); (c) a large proportion of phosphory-
lated FcεRI is also found within these domains relative to 
that outside of these regions (5); and (d) depletion of choles-
terol by pharmacological agents caused reduced phosphory-
lation of FcεRI (5). However, considerable evidence to the 
contrary also exists. Collectively, this apparently contradic-
tory evidence suggests that the presence of FcεRI or Lyn in 
lipid rafts is not essential for FcεRI phosphorylation (10, 15, 
31, 32). We now demonstrate that phosphorylation of FcεRI 
is altered by cholesterol depletion, arguing in favor of a role 
for lipid raft–localized Lyn in this event. However, the ki-
netics of FcεRI phosphorylation were unaltered, suggesting 
that Lyn outside of lipid rafts may also contribute to receptor 
phosphorylation. This latter view is also supported by the 
fact that with 80% of Lyn activity lost from lipid rafts of 
  cholesterol-depleted DHCR KO mast cells, the inhibition of 
receptor phosphorylation was at best 40%. Recent studies 
also demonstrate that mutation of the FcεRIβ ITAM, which 
  ablates the interaction of Lyn with receptor, inhibited the 
initiation of FcεRI phosphorylation (33, 34), arguing that 
protein–protein interaction of Lyn with FcεRI is required 
for either initiation or sustaining phosphorylation. Thus, a 
cohesive model is one in which protein interaction of FcεRI 
with Lyn is important for the initiation of receptor phosp-
horylation, whereas the cholesterol-enriched environment, 
which includes a signifi  cant fraction of Lyn, may function to 
amplify this interaction and sustain receptor phosphorylation. 
This model incorporates the protective phosphatase-defi  cient 
environment of lipid raft domains (30) as important in main-
taining the phosphorylated state of the receptor.
The work described herein also argues that Lyn kinase 
has functions outside as well as inside lipid raft domains. For 
example, one might attribute Cbp phosphorylation as a lipid 
raft localized function of Lyn because Cbp is lipid raft local-
ized and Lyn-null mast cells were equally defective in Cbp 
phosphorylation (20). The phosphorylation of FcεRI and 
Syk, however, is seemingly a function of Lyn both inside and 
outside of lipid rafts. Syk activation, which depends on FcεRI 
phosphorylation, peaked at  50–60% of that in nondepleted 
WT cells (as measured by phosphorylation) but still caused 
sustained LAT phosphorylation and thus normal PLCγ phos-
phorylation and calcium responses. In contrast, Lyn-null mast 
cells showed a marked defect in calcium responses (22, 35, 
36), which is consistent with a more appreciable defect in Syk 
and LAT phosphorylation.
Although the phenotype of cholesterol depletion in WT 
and DHCR KO mast cells is not entirely consistent with 
Lyn-null mast cells, signifi  cant similarities exist. Increased 
  activity of Fyn in DHCR KO cells, relative to cholesterol-
  depleted WT cells, was consistent with Lyn-null mast cells. Loss 
of Cbp phosphorylation was demonstrated to cause increased 
Fyn activity in Lyn-null bone marrow–derived mast cell (20). 
Now we fi  nd that cholesterol-depleted DHCR KO mast 
cells showed a pronounced loss of Cbp phosphorylation 
  relative to that seen in cholesterol-depleted or nondepleted 
WT mast cells. This would indicate that the DHC-mediated 
maintenance of a hyperresponsive mast cell is, at least in part, 
dependent on the loss of Cbp phosphorylation causing in-
creased Fyn kinase activity. It is notable that Fyn kinase activ-
ity was also increased in cholesterol-depleted WT mast cells 
in conjunction with a reduction in Cbp phosphorylation. 
The increased Fyn activity and constitutive activation of Akt 
in both cholesterol-depleted WT and DHCR KO mast cells 
are also consistent with the constitutive secretion of cyto-
kines. Our recent study (37) demonstrates that Fyn is required 
for cytokine production and defi  ciency in Fyn kinase results 
in reduced Akt phosphorylation and nuclear NFκB activity, 
an activity required for both IL-6 and TNF production. 
Although the constitutive activity of Fyn upon cholesterol 
depletion of WT and DHCR KO mast cells was modest 
(WT/WT-/DHCR KO- = 1.0:1.2 ± 0.04:1.5 ± 0.06; P < 
0.05, n = 3), it was signifi  cant and sustained. Thus, the con-
stitutive signaling in the absence of cholesterol could drive 
the cytokine production observed and contribute to the sen-
sitivity of SLOS patients to allergic infl  ammation.
Clinical treatment of SLOS patients includes placing these 
patients on a cholesterol-rich diet, which allows better man-
agement of the multiple aberrant behavioral characteristics 
and enhances patient quality of life, but does little to alter the 
fi  xed developmental abnormalities (38). Reports of allergies 
for these patients are for the most part anecdotal, but an in-
crease in diet cholesterol allows better food tolerance and 
may decrease the frequency of other allergic-like and infl  am-
matory manifestations. Unlike for WT mast cells, cholesterol 
repletion of DHCR KO mast cells did not completely   reverse 
the hyper-degranulation. This suggests that SLOS patients 
possess and maintain (even in the presence of a cholesterol-
rich diet) lipid raft dysfunctions and increased mast cell JEM VOL. 203, May 15, 2006  1169
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sensitivity relative to normal individuals. This is consistent 
with the continued accumulation of DHC in patients on a 
cholesterol-rich diet. Thus, one might speculate that a weak 
allergic stimulus may be suffi   cient to elicit unwanted mast cell 
responses in SLOS. This does not appear to be mediated 
through increased total IgE production, as our initial screen-
ing of patient serum did not reveal abnormal levels (not 
  depicted). Whether increased allergen-specifi  c  IgE  occurs 
in these patients remains to be determined. Regardless, the 
fi  ndings point to a dysregulation of lipid raft function and 
cell signaling as a possible underlying cause of some of 
the developmental and neurological problems in SLOS. The 
observation of lipid raft dysregulation due to DHC strongly 
supports the use of a therapeutic strategy designed to lower 
DHC levels in addition to cholesterol supplementation.
MATERIALS AND METHODS
Antibodies and reagents. mAbs to Syk (clone 4D10), phosphotyrosine 
(clone 4G10), and polyclonal anti-pY191 LAT were from Upstate Biotech-
nology. Rabbit polyclonal antibody to Lyn, Fyn, and goat anti-Cbp (P-18) 
were from Santa Cruz Biotechnology, Inc. Phosphospecifi  c antibodies to 
Syk, Akt, and ERK, as well as mAbs Akt and ERK were from Cell Signaling 
Technology. Rabbit polyclonal anti-Cbp and mouse mAbs anti-LAT were 
provided by T. Yamashita (Hokkaido University, Sapporo, Japan) and 
P. Draber (Institute of Molecular Genetics, Prague, Czech Republic), re-
spectively. Chicken anti-Fyn antibody was prepared by Aves Labs, Inc. using 
peptide sequence C  K  D  K  E  A  A  K  L  T  E  E  R  D  G  S  L  N  Q  S   from the unique do-
main of Fyn. FITC-conjugated monoclonal rat anti–mouse IgE and FITC-
conjugated rat IgG1 monoclonal Ig isotype standard (both used in fl  ow 
cytometry) were from BD Biosciences. Cy5.5-conjugated anti–chicken, 
  avidin, and anti–rabbit antibody, as well as IRDye800-conjugated anti–mouse 
were from Rockland, Inc. Mouse DNP–specifi  c IgE was produced as de-
scribed previously (39). Cell culture media (EMEM, DMEM, and RPMI 
1640) was prepared as described previously (22, 40). β-octyl-glucoside was 
from Pierce Chemical Co., [32P]-ATP was from AP Biomedical, and FURA 
2 was from Invitrogen. Other described reagents were from Sigma-Aldrich.
Cell culture, cell stimulation, degranulation, and cytokine assays. 
Mast cells were cultured from liver progenitors. Cells from the livers of 
newborn mice were isolated using a cell strainer (40 μm; Falcon; BD Bio-
sciences), washed in RPMI media twice, and cultured as described previ-
ously (40) in the presence of 20 ng/ml IL-3 and 20 ng/ml stem cell factor. 
Mast cell populations were monitored for c-KIT and FcεRI expression by 
fl  ow cytometric analysis (41). Mature mast cells were sensitized with anti-
DNP mouse IgE (1 μg per 107 cells) for 2 h in culture medium, and then 
washed twice with Tyrode-BSA buff  er (22, 40). Cell aliquots of 3 × 107 
were resuspended in a total volume of 4 ml Tyrode buff  er, stimulated with 
the indicated Ag concentrations, and sampled at the indicated times.
Degranulation was determined by a colorimetric assay measuring 
β-hexosaminidase activity in a 96-well format essentially as described previ-
ously (40). Cytokine secretion was measured by ELISA (R&D Systems) as 
described previously (37).
Cell lysates, immunoprecipitation, and immunoblotting. Cell lysates 
were prepared in borate buff  er as described previously (42) with the excep-
tion of lysates for immunoprecipitation and analysis of Fyn activity, which 
were solubilized in RIPA buff  er (10 mM NaH2PO4, 50 mM NaCl, 50 mM 
NaF, 0.5% sodium deoxycholate, 0.05% NaN3, 0.1% SDS, 1% Triton, 
1 mM Na3VO4). Cell lysates were precleared with protein A or protein G 
sepharose beads for 1 h and incubated for 2 h with antibodies prebound to 
either protein G sepharose (goat polyclonal) or protein A sepharose (rabbit 
polyclonal). Beads were washed three times, and proteins were recovered 
with 30 μl of 2× concentrated Tris-glycine SDS sample buff  er that con-
tained 1% 2-ME and 1 mM Na3VO4. For immunoblotting, proteins were 
resolved by 8, 10, or 12% SDS-PAGE (Invitrogen) and electrophoretically 
transferred to nitrocellulose membranes (Invitrogen or Schleicher and 
Schuell). Nitrocellulose membranes were blocked with Odyssey blocking 
buff  er (LI-COR Biosciences). They were then probed with the desired pri-
mary antibody in blocking buff  er containing 0.1% Tween-20, and then with 
an appropriate Cy5.5 and/or IRDye800-conjugated secondary antibody and 
visualized by Odyssey Infrared Imaging System (LI-COR Biosciences).
Cholesterol depletion, sterol analysis of cell pellets, preparation and 
solubilization of multilamellar vesicles, and isolation of lipid rafts. 
For cholesterol depletion, cells were incubated in cholesterol-free medium 
with 10% LPDS. LPDS was prepared by organic extraction of FBS in a mix-
ture of n-butanol and isopropylether (5:4:6) for 1 h in the dark and centri-
fuged for 15 min at 4,000 g. The bottom phase was recovered and lyophilized, 
and the resulting pellet was resuspended in original volume. Cholesterol 
content of LPDS was determined by GC/mass spectrometry and found to be 
130 ± 28 pg/ml (normal levels are 10–20 ng/ml). For sterol analysis, cell 
pellets were frozen and thawed twice. After saponifi  cation and lipid extrac-
tion, the cell sterols were subjected to GC/mass spectrometry as described 
previously (43). Protein content of the samples was determined by BCA 
protein assay (Pierce Chemical Co.).
Preparation of multilamellar vesicles was accomplished by extraction of 
lipids from 107 cells with 25 mM HCl methanol/chloroform/1M NaCl 
(1:1:1). The organic phase was assayed for total phospholipid content as de-
scribed previously (44). 500 nmol of total phospholipids from the organic 
phase of each sample was dried under N2 for 20 min. The resulting pellet was 
resuspended in 1 ml PBS with three strokes of ultrasound probe (12% ampli-
fi  cation). Vesicle solubility experiments used 200 μl of multilamellar vesicles 
in a 96-well plate (Immulon 1B). Solubility was achieved by adding 5 μl of 
1% Triton X-100 (10-min intervals) and measuring a decrease in absorbance 
(at 20-s intervals) at 380 and 450 nm on a Fluostar Optima spectrometer 
(BMG Labtechnologies). Solubility of multilamellar vesicles in Triton X-100 
was calculated from the average absorbance at 5 min after the addition of 
  detergent and expressed as the percentage of solubilized liposomes relative 
to total unsolubilized liposomes.
Lipid rafts were isolated as described previously (15) with some modifi  -
cations. In brief, Ag-stimulated (100 ng/ml, 3 min) cells (4.0 × 107) or non-
stimulated cells were lysed in 1 ml of cold 0.1% Triton X-100, which 
contained protease inhibitors, and were homogenized by passing the cells 
through a 25-gauge needle. Homogenates were loaded directly on sucrose 
gradients without preclearing. Gradient fractions were collected from the 
top of the gradient (low to high density), and fractions 1 and 2 or 10 and 11 
were pooled. All other fractions were kept individually. For isolation of Lyn 
from lipid rafts, fractions 1–5 were pooled resuspended in 2× RIPA buff  er 
and Lyn was immunoprecipitated as describe above.
In vitro kinase assay and calcium measurements. The activity of Lyn or 
Fyn kinase was measured by an immune complex in vitro kinase assay. 3.0 × 
107 mast cells were lysed in RIPA buff  er as described above. Lyn and Fyn 
were immunoprecipitated with 5 μg of the appropriate antibody prebound 
to protein A sepharose beads for 3 h at 4°C. Immune-complexed proteins 
were recovered by centrifugation and washed twice with RIPA buff  er fol-
lowed by two additional washes with kinase buff  er (50 mM Hepes, 0.1 mM 
EDTA, 0.015% Triton X-100, 0.07% 2-ME, 10 μM Na3VO4, pH 7.0). 
The in vitro kinase reaction was started by resuspension of the recovered 
pellet in 30 μl of kinase buff  er containing 10 mM ATP, 1 μCi [32P]-labeled 
ATP, and 10 mM MgCl2. 10 μg dephosphorylated casein was added as an 
exogenous substrate. Samples were incubated at 30°C for 20 min with vigor-
ous mixing, and reactions were stopped by the addition of 30 μl 2× SDS 
sample buff  er and immediate boiling for 3 min. Protein A sepharose beads 
were removed by centrifugation, and recovered proteins were resolved by 
SDS-PAGE and transferred to nitrocellulose membranes. Autophosphoryla-
tion of each kinase or phosphorylation of exogenous substrate was detected 
by phosphoimager after transfer of proteins to nitrocellulose membranes. 1170  MAST CELL RESPONSES IN AN SLOS MOUSE MODEL | Kovarova et al.
Protein loading was determined by probing the membranes with appropriate 
antibodies, and quantifi  cation was performed by densitometry.
For calcium measurements, 2 × 106 cells were loaded with IgE 
(1 μg/107 cells) and 2 μM FURA-2/AM (Invitrogen) in RPMI 2% FBS 
media for 45 min at 37°C. Cells were washed twice in Tyrodes-BSA, and 
changes in dye fl  uorescence with time were determined by Fluostar Optima 
spectrometer (BMG Labtechnologies) with excitation wavelengths of 340 
and 380 nm and with a constant emission at 510 nm. Calcium concentra-
tions were calculated as described previously (45).
Online supplemental material. Fig. S1, which shows the kinetics of 
  proliferation of nondepleted WT and cholesterol-depleted WT and DHCR 
KO mast cells, is available at http://www.jem.org/cgi/content/full/jem.
20051701/DC1.
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